Drugs/Recall·openFDA/drug

ONESOURCE SPECIALTY PHARMA LIMITED — Class II: Methohexital Sodium for Injection, USP 500 mg Multiple Dose Vial, Rx Only, Manufactured by

MediumPublished Jul 15, 2026· AI-analyzed Jul 22, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

OneSource Specialty Pharma Limited has initiated a Class II recall of Methohexital Sodium for Injection, USP 500 mg Multiple Dose Vials due to failure to meet impurities and degradation specifications.

Who it affects

This recall affects the manufacturer (OneSource Specialty Pharma Limited), the distributor (Avet Pharmaceuticals Inc.), and healthcare facilities or departments utilizing methohexital sodium for injection (NDC 23155-893-31).

Why it matters

A failure in impurity or degradation specifications suggests a potential loss of product stability or possible manufacturing process variability. While it is a Class II recall, indicating the probability of serious adverse health consequences is remote, regulatory teams should assess the root cause to determine if the issue is batch-specific or indicative of broader systemic gaps in stability monitoring or quality control.

Practical takeaway

QA and procurement teams should verify specific batch numbers and expiration dates against the NDC 23155-893-31 inventory and isolate any units remaining in the distribution chain. Manufacturing teams may need to review impurity profile trends for methohexital sodium production processes.

FDA source material

Class II. Reason: Failed Impurities/Degradation Specifications. Product: Methohexital Sodium for Injection, USP 500 mg Multiple Dose Vial, Rx Only, Manufactured by: OneSource Specialty, Pharma Limited, Bengaluru - 561 203, India, Manufactured for: Avet Pharmaceuticals Inc., East Brunswick, NJ 08816, NDC 23155-893-31. Firm: ONESOURCE SPECIALTY PHARMA LIMITED (Bengaluru N/A India). Status: Ongoing.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.